SUBSCRIBE
SUBSCRIBE
News   Business

Oscient Pharmaceuticals Corporation Provides Financial Projections For Fiscal Year 2006 And 2007

December 8, 2006 | 
1 min read
WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) today provided fiscal year 2006 and 2007 revenue guidance for its products, ANTARA® 130 mg (fenofibrate) capsules and FACTIVE® (gemifloxacin mesylate) tablets.
Earnings
MORE ON THIS TOPIC
Vaccines
Pfizer CEO Blasts HHS’ Anti-Vaccine Policies as Revenue Outlook Dims
December 16, 2025
 · 
3 min read
 · 
Annalee Armstrong
Contemporary art collage. Purple hand holding fan of dollar bills against bright yellow background. stock photo
Venture capital
Ambros Launches With $125M To Bring Italian Non-Opioid Pain Drug to America
December 16, 2025
 · 
1 min read
 · 
Annalee Armstrong
Illustration of businessman running back around
Autoimmune disease
Sanofi Taps Dren Again in up to $1.7B Autoimmune Partnership
December 15, 2025
 · 
1 min read
 · 
Annalee Armstrong
Rheumatoid arthritis (RA) commonly causes inflammation in the hands, leading to pain, swelling, and stiffness in the joints, particularly the small joints of the fingers and wrists. This inflammation results from the immune system attacking the body's own joint tissues, causing the synovium (lining of the joint) to become inflamed and release chemicals that damage nearby tissues.
Mergers & acquisitions
Sobi Makes $1.5B Gout Play With Arthrosi Acquisition
December 15, 2025
 · 
2 min read
 · 
Tristan Manalac